We’re building Compass with a singular goal in mind: unlocking the complexity of the immune system. Our discovery and development teams work together to fully characterize and evaluate novel antibodies and rapidly generate therapeutic candidates. We are leveraging those insights to develop transformational therapies for cancer, inflammation and autoimmune diseases. We are a privately held company; our financing has been led by OrbiMed Advisors, F-Prime Capital, Cowen Healthcare Investments, Thiel Capital, Biomatics Capital, Borealis Ventures, Alexandria Real Estate Ventures and Biomed Realty Ventures.
Some data provided by Crunchbase
EquityZen does not have an affiliation with, formal relationship with, or endorsement from Compass Therapeutics or any companies featured above.
This profile is based on publicly available information and is intended to be informative in nature.
EQUITYZEN and logo are trademarks of EquityZen Inc. Other trademarks are property of their respective owners.
To learn more about whether you're eligible, typical investment size, company valuation, and share price, request access here.